Monographie - Foscarnet sodium - Stabilis 4.0

Ultimo aggiornamento :
19/11/2024

Antivirale

Foscarnet sodium

Iniezione

Stabilità in soluzione

Stabilità in miscela

Fattori che influenzano la stabilità

Compatibilità

metodo di iniezione

Bibliografia

pdf

Struttura chimica

Nome commerciale

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Foscarnet	Argentina, Chile, Stati Uniti d’America
Foscarvir	Giappone
Foscavir	Australia, Austria, Belgio, Francia, Germania, Gran Bretagna, Grecia, Italia, Lussemburgo, nuova Zelanda, Paesi Bassi, Spagna, Stati Uniti d’America, Svezia, Svizzera, Ungheria

Bibliografia

Iniezione

Bibliografia : Foscarnet sodium

	tipo	pubblicazione
2	Rivista	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	Rivista	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	Rivista	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	Rivista	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	Rivista	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	Rivista	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	Rivista	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	Rivista	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratorio	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	Rivista	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	Rivista	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Laboratorio	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Laboratorio	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Rivista	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Laboratorio	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	Rivista	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales